Clinical Evidence - Kaneka Preconception

Ubiquinol promotes sperm health across multiple parameters

Statistically significant increases in sperm count, motility, and morphology after 150-200 mg/day of Kaneka Ubiquinol® for 6 months.1,2*

Not an actual patient.

Not an actual patient.

Study 1

An open-label 6-month study of 60 men with oligospermia, Kaneka Ubiquinol® 150 mg QD vs placebo1

  • Total sperm count increased by 53% (P<0.05)
  • Total sperm motility increased by 26% (P<0.05)
  • Absolute numbers of rapidly swimming sperm increased 41% (P<0.05)


QD=once daily; BID=twice a day.

Not an actual patient.

Study 2

A retrospective 6-month study of 62 men with asthenoteratozoospermia (low sperm motility and abnormal sperm morphology but normal sperm count), Kaneka Ubiquinol® 100 mg BID vs placebo2

  • Fast-moving sperm increased from 5.7% to 11.5% (P<0.001)
  • Sperm morphology improved from 2.6% to 3.1% (P<0.001)*


QD=once daily; BID=twice a day.

References: 1. Thakur AS, Littaru GP, Funahashi I, et al. Effect of Ubiquinol therapy on sperm parameters and serum testosterone levels in Oligoasthenozoospermic infertile men. J Clin Diagn Res. 2015;9(9):BC01-BC03. 2. Cakiroglu B, Eyyupoglu SE, Gozukucuk R, Uyanik BS. Ubiquinol effect on sperm parameters in subfertile men who have astheno-teratozoospermia with normal sperm concentration. Nephro Urol Mon. 2014;6(3):e16870.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

6250 Underwood Road

Pasadena, TX 77507

[email protected]

P: (866) 888-1723

F: (281) 291-4470

Information on this site is for informational purposes only and is intended solely for U.S. healthcare professionals. This content is not intended for and should not be construed as medical advice.

© 2024 Copyright. Kaneka North America LLC. All Rights Reserved.